UAE Cardiac Resynchronization Therapy Market

UAE Cardiac Resynchronization Therapy Market Executive Summary

UAE Cardiac Resynchronization Therapy Market valued at $24 Mn in 2022, projected to reach $38 Mn by 2030 with a 6% CAGR.

Cardiac resynchronization therapy (CRT) involves the use of a pacemaker to correct the heart's rhythm through a minor surgical procedure. Implanted beneath the skin, the CRT pacemaker is responsible for coordinating the timing between the upper (atria) and lower (ventricles) heart chambers, as well as synchronizing the left and right sides of the heart. This intervention is particularly crucial in cases of heart failure, where inadequate pumping results in fluid accumulation in the lungs and legs due to the asynchronous beating of the two lower chambers (ventricles). Additionally, in the presence of severe heart rhythm issues, a physician might suggest an implantable cardioverter-defibrillator (ICD), which can be combined with CRT therapy. The CRT device connects wires from the pacemaker to both sides of the heart, employing biventricular pacing to transmit electrical signals to the ventricles, ensuring coordinated contractions and optimizing overall heart function.

Heart disease, notably heart attacks, is the leading cause of mortality in the United Arab Emirates, responsible for over 40% of all deaths. There's a concerning rise in heart attacks among young adults. Coronary heart disease (CHD) contributes to 80% of cardiovascular disease (CVD) mortality, with Atherosclerotic Cardiovascular Disease (ASCVD) affecting about 40% of adult residents. Many are unaware of their risk until experience serious conditions like heart attacks or strokes. Ischemic heart disease accounts for 52% of male and 21% of female deaths in the UAE, despite comprising 16% of global fatalities.

The Sharjah Institute for Medical Research (SIMR) is collaborating with global partners to develop AI-driven algorithms for the early identification of cardiac rhythm disorders requiring pacemaker implantation. Meanwhile, the Abu Dhabi Telemedicine Centre has initiated a pilot program for remote monitoring of pacemaker patients, enabling real-time data transfer to healthcare providers. This innovative approach ensures prompt treatments and enhances patient outcomes, highlighting the potential of remote monitoring to improve pacemaker users' follow-up care.

Market Dynamics

Market Growth Drivers

Rising Prevalence of Cardiovascular Diseases (CVDs): The UAE's leading cause of death is cardiovascular disorders, with a notable emphasis on the frequency of heart attacks. In the United Arab Emirates, heart disease, particularly heart attacks are the leading cause of mortality, accounting for more than 40% of all fatalities. There is a direct correlation between the growing prevalence of this illness and the rising need for pacemakers. This rise in the need for pacemakers helps in the expansion of the cardiac resynchronization therapy market.

Technological Advancements: The increasing popularity of Cardiac Resynchronization Therapy (CRT) among both patients and physicians can be attributed to technological advancements. These include the development of smaller, more energy-efficient devices with prolonged battery life and advanced functionalities. Patient care is significantly enhanced through features such as remote monitoring and telemedicine capabilities, leading to better outcomes after implantation. The future outlook for CRT appears promising, especially with emerging technologies like leadless pacemakers and artificial intelligence-driven algorithms, indicating potential advancements in the field.

Increased Awareness and Education: Collaborative efforts between healthcare organizations and patient advocacy groups aim to elevate public awareness regarding heart failure and treatment alternatives such as CRT through public health campaigns and educational programs. Increased patient understanding and consciousness can lead to early diagnosis, prompt therapies, and better overall results in the long run.

Market Restraints

Regulatory obstacles: Stringent rules or delays in approving medical devices, including CRT devices, can create difficulties in entering the market and achieving growth. Medical device companies face complex regulatory requirements, and non-compliance can have significant impacts on costs and reputation. The challenge for regulatory bodies is to strike a balance between ensuring the safety and effectiveness of products without unduly slowing down the approval process.

High Cost of CRT Devices: The cost of CRT devices is considerable, varying from tens of thousands to hundreds of thousands of dollars. For patients, especially those with limited financial resources or inadequate insurance coverage, this large cost may provide a major challenge. Patients may have significant out-of-pocket costs even with insurance, which deters them from seeking CRT therapy.

Limited Access to Specialists: The implantation of CRT devices demands specific skills and training. The scarcity of trained electrophysiologists and other specialists, especially in locations outside major cities, may hinder many patients' access to this therapy.

Healthcare Policies and Regulatory Landscape

In the United Arab Emirates (UAE), the management of healthcare policies and regulatory control over treatment drugs is primarily overseen by key entities such as the Ministry of Health and Prevention (MOHAP), Health Authority Abu Dhabi (HAAD), Dubai Health Authority (DHA), Emirates Health Services Establishment (EHSE), and the Pharmaceutical Services Department (PSD). MOHAP, serving as a central regulatory authority, plays a crucial role in the creation and implementation of healthcare policies, with a focus on ensuring the safety, effectiveness, and quality of pharmaceuticals. Additionally, regional health authorities like HAAD and DHA are responsible for overseeing healthcare services, including drug regulations, within their respective emirates. EHSE contributes to regulations at the federal level, and PSD, operating under MOHAP, concentrates on activities related to pharmaceuticals. The Centralized Procurement Office (CPO) is actively involved in the acquisition of pharmaceuticals for public healthcare facilities, with a commitment to maintaining adherence to regulatory standards.

Competitive Landscape

Key Players

• Abbott
• Boston Scientific
• Medtronic
• Siemens Healthineers
• Johnson & Johnson
• Biotronik
• LivaNova
• MicroPort
• Sorin Group
• St. Jude Medical